Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $6

HC Wainwright & Co. analyst Andrew Fein maintains Epizyme (NASDAQ:EPZM) with a Buy and lowers the price target from $8 to $6.
byBenzinga Newsdesk
June 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Andrew Fein maintains Epizyme (NASDAQ:EPZM) with a Buy and lowers the price target from $8 to $6.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0